| Sector |
Miscellaneous
|
Compare with Sector peers |
| Industry |
Miscellaneous
|
Compare with Industry peers |
| Website | http://www.vantabio.com | |
| Market Cap | 43.17 Cr. | |
| Enterprise Value(EV) | 76.49 Cr. | 2021-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.14 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 490.61 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 15.82 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 37.89 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 1.81 | Calculated using Price: 68.40 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 0.63 Cr. | 6,312,000 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The company is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition they also provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. Their services include toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation. | ||
| 1 Day |
|
-5.00% |
| 1 Week |
|
-9.75% |
| 1 Month |
|
-10.37% |
| 3 Month |
|
+1.53% |
| 6 Month |
|
-22.60% |
| 1 Year |
|
-47.43% |
| 2 Year |
|
-64.74% |
| 5 Year |
|
+33.70% |
| 10 Year |
|
| 3 years | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 3.14 | 4.43 | 1.89 | |
| Return on Capital Employed (%) | 7.87 | 8.62 | 5.42 | |
| Return on Assets (%) | 1.78 | 2.31 | 0.76 |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Shh. Funds | 22 | 23 | 24 | |
| Non Curr. Liab. | 13 | 14 | 29 | |
| Curr. Liab. | 3 | 10 | 15 | |
| Minority Int. | 1 | 1 | 2 | |
| Equity & Liab. | 39 | 49 | 70 | |
| Non Curr. Assets | 22 | 29 | 50 | |
| Curr. Assets | 17 | 20 | 20 | |
| Misc. Exp. not W/O | ||||
| Total Assets | 39 | 49 | 70 |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 12 | 14 | 10 | |
| Other Income | 0 | 0 | 0 | |
| Total Income | 12 | 14 | 10 | |
| Total Expenditure | -9 | -9 | -6 | |
| PBIDT | 4 | 4 | 4 | |
| Interest | -2 | -2 | -2 | |
| Depreciation | -1 | -1 | -1 | |
| Taxation | 0 | 0 | 0 | |
| Exceptional Items | ||||
| PAT | 1 | 1 | 0 | |
| Minority Interest | 0 | |||
| Share Associate | ||||
| Other Related Items | ||||
| Consolidated Net Profit | 1 | 1 | 0 | |
| Adjusted EPS | 1 | 2 | 1 |
| Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | -1 | 2 | 7 | |
| Cash Fr. Inv. | -6 | -7 | -22 | |
| Cash Fr. Finan. | 10 | 2 | 18 | |
| Net Change | 3 | -3 | 2 | |
| Cash & Cash Eqvt | 3 | 0 | 3 |
|
Fri, 10 Mar 2023
Vayam Research Solutions Limited Associate Company (Indirect) Of Vanta Bioscience Limited Has Cleared USFDA Audit With Zero 483S Vayam Research Solutions Limited Associate Company (indirect) of Vanta Bioscience Limited has cleared USFDA audit with Zero 483s |
|
Wed, 15 Feb 2023
Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP) Settlement with the Operational Creditor - Order of Supreme Court |
|
Sat, 21 Jan 2023
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Outcome of the First Meeting of Committee of Creditors of Vanta Bioscience Limited |
| Fri, 17 Mar 2023 |
Opening at High
|
Opening at Low
|
Opening at High for 3 days
|
Closing Below Previous Low
|
Closing Below Previous Low for 3 days
|
Equities
M.F.
Sectors